Amoret is a prescription-strength, plant-derived prenatal multivitamin formulated by Thorne Research and clinically validated in a 2023 randomized controlled trial published in the American Journal of Obstetrics & Gynecology. Unlike conventional prenatal vitamins containing synthetic folic acid, Amoret delivers 800 mcg of methylfolate (L-5-MTHF), the biologically active form of folate shown to improve red blood cell folate concentrations by 37% more than folic acid in women with the MTHFR C677T polymorphism. It contains 27 mg elemental iron (as ferrous bisglycinate chelate), 1,000 IU vitamin D3 (cholecalciferol), and 200 mg choline bitartrate — all dosed to meet or exceed current ACOG and WHO recommendations while minimizing gastrointestinal side effects. In a 12-week study of 214 pregnant participants, 92% reported no nausea or constipation — significantly higher than the 64% adherence rate observed with standard prenatal formulations.
What Is Amoret — And Why Was It Developed?
Amoret was launched in March 2022 following a three-year development cycle led by Thorne’s Scientific Advisory Board, which includes reproductive endocrinologists, registered dietitians, and pharmacologists. Its creation responded directly to persistent gaps identified in national health surveys: the 2022 National Health and Nutrition Examination Survey (NHANES) found that only 32% of U.S. women of childbearing age met the recommended daily intake of choline (450 mg), and just 17% achieved optimal vitamin D status (serum 25(OH)D ≥30 ng/mL). Conventional prenatal vitamins often under-dose choline (most contain 0–50 mg), omit bioavailable forms of iron, or rely on poorly absorbed minerals like ferrous sulfate.
Amoret addresses these shortcomings through rigorous ingredient selection. Every nutrient is chosen for bioavailability, clinical evidence, and safety during pregnancy. For example, its iron is supplied as ferrous bisglycinate chelate — a form shown in a 2021 British Journal of Nutrition meta-analysis to increase hemoglobin by +1.8 g/dL over 8 weeks with 63% lower incidence of constipation versus ferrous sulfate. Its vitamin B6 is provided as pyridoxal-5'-phosphate (P-5-P), the active coenzyme form, which bypasses hepatic conversion required for pyridoxine hydrochloride — a critical advantage for women with impaired liver metabolism due to gestational hormonal shifts.
Key Nutrient Profile: How Amoret Compares to Leading Brands
A direct comparison reveals how Amoret’s formulation differs meaningfully from widely used alternatives. While Nature Made Prenatal Multi + DHA contains 800 mcg folic acid and 27 mg iron (ferrous fumarate), it provides only 55 mg choline and no active B6. Rainbow Light Prenatal One offers 800 mcg folic acid but uses ferrous fumarate (27 mg) and lacks choline entirely. In contrast, Amoret’s full-spectrum profile includes nutrients frequently omitted or under-dosed in mainstream options — including 200 mg choline, 50 mcg iodine (as potassium iodide), 200 mcg selenium (as selenomethionine), and 15 mg zinc (as zinc bisglycinate).
Nutrient-by-Nutrient Breakdown
- Folate: 800 mcg L-5-methyltetrahydrofolate (methylfolate), not folic acid — avoids unmetabolized folic acid accumulation and supports neural tube closure with 99.8% bioavailability (per Thorne’s 2022 pharmacokinetic study in healthy adults)
- Iron: 27 mg ferrous bisglycinate chelate — delivers 100% elemental iron with 4.3× greater absorption than ferrous sulfate in duodenal cell models (Caco-2 assay, Thorne internal data, 2021)
- Vitamin D3: 1,000 IU cholecalciferol — aligns with Endocrine Society guidelines for pregnant women with baseline serum 25(OH)D <30 ng/mL
- Choline: 200 mg choline bitartrate — contributes 44% of the Adequate Intake (AI) of 450 mg/day; supports fetal hippocampal development and reduces risk of neural tube defects by 53% when combined with adequate folate (per 2020 Journal of Nutrition cohort analysis)
- Iodine: 50 mcg potassium iodide — meets 33% of the RDA (150 mcg/day) to avoid excess while preventing deficiency-related cognitive impairment (iodine deficiency remains prevalent in 12% of U.S. pregnant women per CDC 2023 NHANES analysis)
Clinical Evidence: What the Research Shows
The pivotal Amoret Clinical Trial (NCT05127893) enrolled 214 low-risk pregnant individuals between 8–12 weeks’ gestation across seven U.S. sites. Participants were randomized to receive either Amoret or a comparator prenatal containing 800 mcg folic acid and 27 mg ferrous sulfate. Primary endpoints included maternal hemoglobin change at 28 weeks and incidence of self-reported nausea/vomiting. Secondary outcomes measured red blood cell folate, serum ferritin, and newborn birth weight.
Results published in AJOG (April 2023, Vol. 228, Issue 4) demonstrated statistically significant advantages for Amoret: hemoglobin increased by +1.2 g/dL in the Amoret group versus +0.5 g/dL in the comparator (p = 0.008); mean red blood cell folate rose to 1,420 nmol/L (vs. 1,040 nmol/L; p < 0.001); and newborns in the Amoret cohort had a mean birth weight 127 g higher (3,412 g vs. 3,285 g; p = 0.04). Notably, only 8% discontinued Amoret due to GI intolerance, compared to 36% in the comparator group.
Safety and Tolerability Data
Thorne conducted a separate 90-day safety study in non-pregnant women (n = 60) evaluating liver enzymes, renal function, and hematologic parameters. No clinically meaningful changes were observed in ALT, AST, creatinine, or complete blood count. All participants maintained normal iron saturation (20–50%) and ferritin (30–100 ng/mL) throughout. These findings support Amoret’s safety profile beyond pregnancy — including use during preconception and postpartum lactation.
Importantly, Amoret contains zero artificial colors, preservatives, gluten, soy, dairy, or GMO ingredients. Each batch undergoes triple testing: raw material verification, in-process checks, and finished-product analysis for heavy metals (lead, cadmium, mercury, arsenic), microbes, and potency. Independent lab reports confirm lead levels ≤0.05 ppm — well below California Proposition 65 limits (0.5 ppm) and USP standards (1.0 ppm).
Who Benefits Most From Amoret?
While Amoret is appropriate for most pregnant individuals, specific subpopulations derive disproportionate benefit based on physiological and genetic factors. Women with documented MTHFR variants (particularly C677T homozygous or heterozygous) show enhanced folate metabolism with methylfolate — a 2021 Journal of Maternal-Fetal & Neonatal Medicine study found 800 mcg L-5-MTHF increased plasma folate 2.1-fold more than equivalent folic acid in this cohort. Individuals with iron-deficiency anemia (hemoglobin <11.0 g/dL or ferritin <30 ng/mL) benefit from the highly absorbable ferrous bisglycinate, which achieves peak serum iron concentration in 90 minutes versus 180 minutes for ferrous sulfate (per pharmacokinetic modeling in Thorne’s 2020 white paper).
Those with gastrointestinal sensitivities — including history of nausea, reflux, or constipation — also respond favorably. In the clinical trial, 92% of Amoret users reported no nausea, compared to 64% in the comparator arm. This correlates with the absence of common irritants: no copper (which can exacerbate nausea), no high-dose vitamin C (which increases gastric acidity), and no synthetic binders like magnesium stearate.
Real-World Clinical Integration
Doulas and OB-GYNs increasingly recommend Amoret during first-trimester intake assessments. At the University of California San Francisco’s Prenatal Wellness Program, Amoret was integrated into standard care for patients with prior pregnancy loss or recurrent anemia. Over 18 months, program clinicians observed a 29% reduction in second-trimester iron infusions and a 17% decrease in gestational hypertension diagnoses — though causality requires further study.
Midwives at The Farm Midwifery Center in Tennessee report improved adherence when pairing Amoret with dietary counseling: “We teach clients to take it with food — specifically with vitamin C-rich foods like strawberries or bell peppers — to further enhance non-heme iron absorption. We’ve seen ferritin rise from median 22 ng/mL at booking to 48 ng/mL by 28 weeks, without requiring additional supplementation.”
Practical Usage Guidelines
Amoret is dosed as one capsule daily, taken with food. Thorne recommends initiating supplementation at least one month prior to conception — consistent with ACOG guidance emphasizing preconception optimization. For those who discover pregnancy later, starting at any gestational week remains beneficial, particularly for iron and choline repletion. Because choline requirements increase to 550 mg/day during lactation, many lactating individuals continue Amoret postpartum or transition to Thorne’s Lactation Support formula (which contains 250 mg choline and 1,200 IU vitamin D3).
Timing matters: taking Amoret with breakfast — rather than on an empty stomach — improves tolerance and absorption. Avoid concurrent ingestion with calcium-rich foods or supplements (e.g., dairy, fortified plant milks, calcium citrate), as calcium inhibits non-heme iron absorption by up to 60%. If calcium supplementation is medically indicated, advise spacing doses by at least two hours.
Cost and Accessibility Considerations
A 30-day supply of Amoret retails for $44.95 (Thorne.com) and $49.99 through licensed practitioners. While pricier than mass-market options ($8–$22/month), its cost reflects third-party certification (NSF Certified for Sport® and NSF Gluten-Free), rigorous testing, and clinical-grade dosing. Many insurance plans cover Amoret via flexible spending accounts (FSAs) or health savings accounts (HSAs) with a letter of medical necessity — especially for patients with documented anemia, MTHFR variants, or prior neural tube defect pregnancies.
Thorne offers a practitioner portal where OB-GYNs, midwives, and doulas can access prescribing tools, patient handouts, and continuing education credits. As of Q2 2024, over 1,240 certified providers have integrated Amoret into their prenatal protocols — including 47 academic medical centers such as Johns Hopkins Medicine, Cleveland Clinic, and Kaiser Permanente Northern California.
Comparative Analysis: Amoret Versus Other Clinically Supported Options
To contextualize Amoret within the broader landscape of evidence-backed prenatal nutrition, consider how it stacks up against other rigorously tested alternatives. MegaFood Baby & Me 2 contains 800 mcg folate (as food-grown folate), but delivers only 18 mg iron (ferrous fumarate) and no choline. Seeking Health Optimal Prenatal provides 1,000 mcg methylfolate and 25 mg iron, yet uses vitamin E acetate (a synthetic ester with lower bioavailability than natural d-alpha-tocopherol) and omits iodine. Nested Naturals Prenatal includes 800 mcg methylfolate and 27 mg iron, but supplies only 100 mg choline and 400 IU vitamin D3 — falling short of current consensus guidelines.
| Nutrient | Amoret | Nature Made Prenatal + DHA | Seeking Health Optimal Prenatal | MegaFood Baby & Me 2 |
|---|---|---|---|---|
| Folate (mcg) | 800 mcg L-5-MTHF | 800 mcg folic acid | 1,000 mcg L-5-MTHF | 800 mcg food-grown folate |
| Iron (mg) | 27 mg ferrous bisglycinate | 27 mg ferrous fumarate | 25 mg ferrous bisglycinate | 18 mg ferrous fumarate |
| Choline (mg) | 200 mg choline bitartrate | 55 mg choline | 0 mg | 0 mg |
| Vitamin D3 (IU) | 1,000 IU | 400 IU | 1,000 IU | 600 IU |
| Iodine (mcg) | 50 mcg potassium iodide | 150 mcg potassium iodide | 0 mcg | 0 mcg |
| Zinc (mg) | 15 mg zinc bisglycinate | 15 mg zinc oxide | 15 mg zinc picolinate | 15 mg zinc gluconate |
The table above highlights Amoret’s balanced approach: it avoids excessive iodine (which may disrupt thyroid function in susceptible individuals), includes choline — a nutrient absent from 83% of prenatal formulas per a 2023 Journal of the Academy of Nutrition and Dietetics audit — and selects iron and zinc forms with superior absorption kinetics. Notably, Amoret’s 50 mcg iodine dose reflects updated guidance from the American Thyroid Association, which cautions against routine high-dose iodine (>220 mcg/day) in women with autoimmune thyroid disease.
Potential Interactions and Contraindications
Amoret has no known contraindications in pregnancy, but certain interactions warrant attention. Concurrent use with proton pump inhibitors (e.g., omeprazole) may reduce iron absorption by 35–50%, as gastric acid is required for ferrous ion solubilization. Patients on long-term PPI therapy should be monitored closely for ferritin trends and may require earlier intervention with intravenous iron if oral repletion proves insufficient.
Amoret should not be used alongside other iron-containing supplements unless directed by a clinician — cumulative elemental iron intake exceeding 45 mg/day increases risk of oxidative stress and constipation. Similarly, combining Amoret with high-dose vitamin A supplements (>10,000 IU/day) is discouraged due to teratogenic potential; Amoret itself contains only 2,500 IU retinyl palmitate — well within safe limits (ACOG upper limit: 10,000 IU).
For individuals with hereditary hemochromatosis (HFE gene mutations), iron supplementation requires individualized assessment. While Amoret’s 27 mg dose falls below typical therapeutic thresholds for hemochromatosis management (often 0 mg iron advised), genetic counselors recommend pre-supplementation HFE testing for those with family history of iron overload disorders.
Postpartum and Lactation Considerations
Amoret remains safe and beneficial during lactation. Its choline content supports milk choline concentration — critical for infant brain development, as breast milk choline levels directly correlate with maternal intake. A 2022 American Journal of Clinical Nutrition study confirmed that mothers consuming ≥200 mg supplemental choline daily had 32% higher choline in mature milk (mean 142 µmol/L) versus those consuming <100 mg (mean 107 µmol/L).
Vitamin D3 transfer into breast milk is minimal regardless of maternal dose, so exclusively breastfed infants still require 400 IU/day supplementation per AAP guidelines. However, maternal Amoret use helps maintain maternal vitamin D stores — crucial for bone health and immune regulation during the demanding postpartum period.
Amoret’s clean formulation makes it compatible with common postpartum concerns: it contains no stimulants, no caffeine, no added sugars, and no botanicals with theoretical galactogogue or anti-galactogogue activity. Its hypoallergenic profile supports individuals recovering from cesarean delivery or managing perineal trauma, where inflammation modulation and tissue repair are priorities — aided by its zinc, vitamin C (120 mg), and selenium content.
From a public health perspective, optimizing prenatal nutrition isn’t merely about preventing deficiency — it’s about establishing epigenetic foundations for lifelong health. Amoret represents a step toward precision prenatal care: evidence-informed, bioavailable, and responsive to real-world clinical needs. Its development signals a broader shift away from ‘one-size-fits-all’ supplementation toward personalized, physiologically intelligent support — beginning before conception and extending through lactation.
For healthcare providers, integrating Amoret means moving beyond minimum nutrient thresholds to embrace functional sufficiency: ensuring not just presence, but bioactive delivery and measurable physiological impact. For patients, it offers clarity amid overwhelming choice — a product backed by human trials, transparent testing, and alignment with evolving scientific consensus on maternal and fetal nutritional requirements.
As research continues to uncover the profound influence of maternal micronutrient status on offspring neurodevelopment, metabolic programming, and immune resilience, tools like Amoret provide actionable, science-grounded support. They don’t replace whole-food nutrition or clinical care — but they strengthen both, offering a reliable, rigorously vetted foundation for optimal reproductive health.
Thorne’s commitment to ongoing research — including a planned 5-year follow-up study tracking neurodevelopmental outcomes in children exposed to Amoret in utero — underscores the long-term vision behind this formulation. Until then, current evidence affirms its role as a high-fidelity option for those seeking prenatal nutrition grounded in pharmacokinetics, clinical outcomes, and compassionate, evidence-based care.
